Treatment of a giant hepatic echinococcal cyst with percutaneous drainage and in vivo assessment of the protoscolicidal effect of praziquantel

Joachim Richter1 · Andreas Karl Lindner1 · Dominik Geisel2 · Giovanni Federico Torsello2 · Gabriela Equihua Martinez1 · Caroline Isner3 · Dirk Schürmann3 · Frieder Pfäfflin3 · Arzu Orhun4 · Tommaso Manciulli5 · Enrico Brunetti5,6

Received: 27 January 2021 / Accepted: 19 March 2021 / Published online: 13 April 2021
© The Author(s) 2021

Abstract
Therapy choices for cystic echinococcosis (CE) are stage-specific: surgical, minimally invasive, medical or observation without intervention. PAIR (percutaneous aspiration, instillation of a scolicide, and re-aspiration) has been considered the treatment of choice for uncomplicated echinococcal liver cysts. However, PAIR carries the risk of toxic cholangitis or hypernatremia and that the cyst frequently refills with bile after withdrawing the catheter. We treated a patient with a giant CE 1 liver cyst with puncture drainage (PD) under albendazole coverage. Drainage enabled us to monitor the morphology of protoscolices under praziquantel (PZQ) co-medication. Protoscolices degenerated within 5 days of PZQ 50 mg/kg/d. The cyst cavity solidified with no evidence of reactivation or secondary spread. Percutaneous treatments can replace surgery in a significant number or cases with hepatic CE. PD allows to assess microscopically the viability of protoscolices under co-medication with PZQ–albendazole and to avoid the instillation of topical scolicides.

Keywords Cystic echinococcosis · Echinococcus granulosus · Percutaneous drainage · Praziquantel · Albendazole

Introduction
The clinical management of cystic echinococcosis (CE) is complex, as the various manifestations of this disease with multiple variables such as cyst number, dimension, stage, anatomical location make a systematic analysis difficult. An expert group convened by the World Health Organization has proposed a more rational approach to CE through a standardized ultrasound classification of echinococcal cysts [1, 2]. Hepatic echinococcal cysts were classified according to their morphology and activity (Fig. 1) [1, 2]. This enables a stage-appropriate treatment decision. Current therapy options include surgical procedures, percutaneous therapy, conservative therapy with antihelminthics and observation without intervention (“watch & wait”) of inactive cysts. If invasive interventions are planned, these must be carried out under an anti-helminthic coverage with a benzimidazole, preferably albendazole [1–5].
Case report

A 30-year-old Kurdish patient from Syria visited the Institute for Tropical Medicine in Berlin because of suspected CE of the liver. Ten days earlier, a cholecystectomy had been performed because of acute gallbladder hydrops due to the compression of the cystic duct by a large liver cyst. The surgeons decided against removal of the large cyst during the emergency surgery. When the patient visited our outpatient department, the imaging showed a typical CE1 liver cyst with a characteristic external echogenic wall and a size of 15.5 × 9.2 × 8.1 cm (Fig. 1, 2a). The CE was confirmed by positive specific antibody test results: *Echinococcus granulosus* EIA IgG 92 AU (antibody units; norm: < 15; Euroimmun. Lübeck, Germany); HAT IgG 1: 1024 (Norm: 1: 32–1: 64; Siemens, Erlangen, Germany).

Secondary extrahepatic dissociation of CE was excluded by abdominal CT and imaging of the lungs and brain.

Albendazole (ABZ) therapy was started with a standard dose of 2 × 400 mg/day. After carefully examining all treatment options, we decided on a minimally invasive approach: a lockable 12-F drainage catheter (multi-purpose drainage catheter, Cook Inc., Bloomington, USA) was percutaneously inserted into the liver cyst using a Seldinger approach inserted into the liver cyst and fixed to the skin with a suture (Fig. 2b). Allergic events did not occur either during or after the procedure. PZQ was added to the ABZ medication in a daily dose of 50 mg/kg body weight. More than 1500 ml of fluid was drained from the collapsed cyst in the following days. As a result, the cyst membrane collapsed and the cyst morphology converted into CE3a. Microscopy of the cyst material aspirated through the catheter on the first day showed a large number of morphologically intact protoscolices despite the previous 21-day ABZ administration. Within
5 days after adding PZQ to ABZ, the protoscolices degenerated completely. The hooks had lost their morphological alignment in the rostellum, (Fig. 3). The ABZ-sulfoxide serum concentration was found < 0.43 mg/l, a concentration below the defined efficacy level of 0.5–1.7 mg/l. This confirmed the protoscolicial effect of PZQ in vivo, although PZQ concentration in the cyst fluid and serum could not be determined for logistic reasons.

Another 4 months later, the cyst cavity had narrowed to 5.0 cm and solidified into a CE4 cyst until last seen 23 months later. Thus, the ABZ therapy was ended. During the 23-month monitoring period to date, there has been no evidence of a relapse or occurrence of secondary CE (Fig. 4). The antibody serum concentration decreased to EIA IgG 20 AU and the specific HAT test turned negative.

Discussion

Surgical intervention is still the first choice for complicated abdominal cysts and hepatic cysts in stage CE2 and CE3b. This also applies to cysts with less common extra-abdominal locations such as heart, lung, CNS and bone CE, that often do not respond to conservative therapy [1, 2, 4, 6, 7]. Surgical therapy must be carried out under benzimidazole (BMZ), such as ABZ or mebendazole (MBZ), coverage to avoid secondary echinococcosis after accidental leakage of cyst fluid into the peritoneum [1, 2, 5, 8].

Conservative BMZ therapy is the best option for treating small cysts less than 5 cm in diameter in stage CE1 and CE3a or when the CE already affects several organs [1, 2, 4, 9]. If ABZ is not tolerated, MBZ can be given instead.

Larger uncomplicated CE1 and CE3a cysts can be treated with percutaneous treatments depending on their size [1, 2, 4, 9]. Puncture, aspiration, topical instillation of a scolicide and re-aspiration (PAIR) has been recommended as the first-line therapy option for simple CE1 cysts. 98% ethanol or 20% saline solution are most commonly used as scolicidals [1, 2, 4, 9]. The risk of anaphylaxis when puncturing a hepatic CE cyst under ABZ coverage appears to be comparable to that of surgery [10–13]. On the other hand, topical intracystic scolicidals bear several risks that increase in direct proportion to the cyst size: highly concentrated ethanol can cause severe chemical cholangitis when accidental leakage into the biliary tree.

Fig. 3 Microscopy of the cyst fluid: a multitude of viable protoscolices at puncture, 21 days after starting albendazole monotherapy; b single protoscolex; c intact rostellum with hooklets; d degenerating protoscolex; e disintegrated rostellum five days after adding praziquantel

Fig. 4 a–c Abdominal ultrasonography: subsequent evolution of the liver cyst after aspiration and combined albendazole—praziquantel therapy. a after having 13 withdrawn 1500 ml of cyst fluid; b one week after removal of the catheter; c twenty-three months after PD
system occurs [2, 4]. Hypertonic saline has been reported 
to sometimes cause severe or even fatal hypernatremia 
[14–16]. Furthermore, in the case of a PAIR, in which the 
catheter is usually removed immediately after aspiration, 
bile frequently flows into the cyst cavity, which can falsely 
give the impression of a relapse and solidification of the 
cyst is delayed. For these reasons, we opted for a percu-
taneous drainage (PD) which has been recommended for 
“giant” cysts > 10 cm [1, 17, 18]. Instead of an intracystic 
instillation of a scolicide, we added the oral scolicidal 
anti-helminthic drug praziquantel (PZQ) [1, 17–22]. In 
humans, PZQ inhibits the vesicular development of proto-
scolices and thus prevents the formation of secondary 
cysts. PZQ also inhibits cyst differentiation and the devel-
opment of the fibrous adventitial layer. PZQ is consider-
ably more effective against intracystic protoscolices than 
ABZ in vitro and in animal models [3, 17–22]. The data 
on whether PZQ alone is also sufficiently protoscolicidal 
in vivo, or whether this is partly due to a synergy with 
ABZ, are contradictory [19–22]. Therefore, the data situ-
ation does not yet allow a general recommendation for the 
PZQ dosage and duration of therapy to be formulated [22]. 
In the present case, the drainage was left in place until the 
cyst collapsed completely and only minimal amounts of 
fluid emerged from the catheter. This enabled us to exam-
ine the cyst aspirate microscopically and to assess the mor-
phology of the intracystic protoscolices at any time. Since 
ABZ pretreatment without PZQ had not affected the proto-
scolices and the ABZ serum concentration remained below 
the specified therapeutic serum concentration 2 days after 
the additional administration of PZQ, we assume that the 
protoscolicidal effect was mainly due to PZQ. Repeated 
microscopy of the cyst fluid documented the degenera-
tion of the protoscolices in vivo, which occurred within 
5 days after adding PZQ for at a dose of 50 mg/kg body 
weight/day an observation essentially confirmed by two 
other cases that we treated according to the same protocol 
(not listed here).

Cystic echinococcosis (CE) is a worldwide widespread 
zoonosis that has been included by the WHO into the list 
of Neglected Tropical Diseases (NTD). In this context, CE 
is classified as an “orphan disease” [24]. CE mainly occurs 
in areas where slaughter is not controlled. Dogs become 
infected when they have access to infected offals. Human 
infection is acquired through direct or indirect contact with 
dog feces and subsequent ingestion of taenia eggs [4]. Mea-
ures to prevent transmission include hygienic measures, the 
physical separation of dogs and farm animals, controlled 
slaughter of livestock, boiling offal before it is fed to dogs 
and regular PZQ deworming of dogs. No final recommen-
dation can yet be made regarding the effectiveness of sheep 
vaccines. Control measures are effective but take time to 
achieve disease control and their cost-effectiveness depends 
on the burden of disease. [4, 25]. A Canadian study has 
shown that these measures are cost-effective at least when 
the prevalence of CE exceeds 13/100,000 people [26]. 

In non-endemic areas, CE mainly affects refugees and 
immigrants from rural areas, where the prevalence of CE 
can exceed 5% [27]. In terms of treatment, the stage-matched 
approach to liver cysts allows a rational choice that avoids 
ineffective (ABZ or PAIR for CE2 and CE3b cysts) or 
unnecessary over-treatment. Any surgery on uncomplicated 
inactive cysts is potentially dangerous and a waste of med-
ical resources [1, 4, 23, 28].

Concluding, CE is a global zoonosis that requires a 
complex, stage-appropriate, multidisciplinary therapeutic 
approach. Optimal treatment of hepatic echinococcosis 
depends on the WHO staging through imaging (Fig. 1). 
Surgical therapy is usually necessary for CE2 and CE3b 
liver cysts. CE4 and CE5 liver cysts are observed without 
treatment. Unilocular echinococcal cysts (CE1, CE3a) can 
be treated conservatively or minimally invasively: for CE1 
cysts < 5 cm, a purely drug-based treatment attempt with a 
BMZ can be made, for CE1 cysts of 5–10 cm a PAIR is the 
first choice, for CE1 cysts > 10 cm a PD is indicated. The 
protoscolicidal PZQ can replace potentially harmful topical 
protoscolicidals. When a PD is performed, the microscopic 
monitoring of the larvae in the cyst aspirate allows the indi-
vidual optimal PZQ treatment dose and duration to be deter-
mined. Conservative and percutaneous therapy can replace 
invasive surgical interventions in a significant number of 
cases and thus reduce the length of hospital stay, complica-
tions and intervention costs, which is of particular impor-
tance in resource-poor endemic areas. In the present case, 
the cumulative length of hospital stay was 9 days, compared 
to an average length of hospital stay of a surgically treated 
patient of 20 days [28].

Acknowledgements There was no specific financial support. The case 
was managed in a routine clinical context. We thank Prof. Dr. Ralf 
Kubitz, Moers for providing the schematic representations in Fig. 1.

Author contributions JR, AKL, DG, GFT, GEM, DS, FP examined 
and cared for the patient, JR, AO, TM and EB carried out the literature 
research and discussed the case. All authors contributed to the drafting 
of the manuscript.

Funding Open Access funding enabled and organized by Projekt 
DEAL.

Declarations

Conflict of interest The authors declare that they have no conflict of 
interest.

Human/animal rights All procedures followed were in accordance with 
the ethical standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki Declaration 
of 1975, as revised in 2008.
Informed consent  Informed consent was obtained from the patient included in the study.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114:1–16.
2. WHO Informal Working Group on Echinococcosis (IWGE). PAIR: Puncture, Aspiration, Injection, Re-Aspiration. WHO/CDS/CSR/APH/2001; 30: 1–10.
3. Velasco-Tirado V, Alonso-Sardón M, Lopez-Bernus A, et al. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis. 2018;18:306.
4. Stojkovic M, Gottstein B, Junghanss T. Echinococcosis. In: Manson’s Tropical Diseases. 2014.
5. Akta AO, Yalin R. Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Eur J Gastroenterol Hepatol. 1996;8:877.
6. Cattaneo L, Manciulli T, Cretu C-M, et al. Cystic Echinococcosis of the bone: a European multicenter study. Am J Trop Med Hyg. 2019;100:617–21.
7. Thapa B, Sapkota R, Kim M, Barnett SA, Sayami P. Surgery for parasitic lung infestations: roles in diagnosis and treatment. J Thorac Dis. 2018;10:S3446–57.
8. Velasco-Tirado V, Romero-Alegria A, Pardo-Ledias J, et al. Management of cystic echinococcosis in the last two decades: what have we learned? Trans R Soc Trop Med Hyg. 2018;112:207–15.
9. Khuroo MS, Dar MY, Yattoo GN, et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology. 1993;104:1452–9.
10. Neumayr A, Troia G, de Bernardis C, et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis—a systematic literature review. PLoS Negl Trop Dis. 2011;5:e1154.
11. Richter J, Profis E, Hoflfreter MC, et al. Anaphylactic shock ensuing therapeutic puncture of an echinococcal cyst. Parasitol Res. 2015;114:763–6.
12. Li Y, Zheng H, Cao X, Liu Z, Chen L. Demographic and clinical characteristics of patients with anaphylactic shock after surgery for cystic echinococcosis. Am J Trop Med Hyg. 2011;85:452–5.
13. Sokouti M, Sadeghi R, Pashazadeh S, et al. A systematic review and meta-analysis on the treatment of liver hydatid cyst using meta-MUMS tool: comparing PAIR and laparoscopic procedures. Arch Med Sci. 2019;15(2):284–308.
14. Krige JE, Millar AJ, Rode H, Knobel D. Fatal hypernatraemia after hypertonic saline irrigation of hepatic hydatid cysts. Pediatr Surg Int. 2002;18(1):64–5.
15. Michalodimitrakis M, Nathena D, Mavroforou A, Papavdi A, Kranioti EF. Fatal hypernatremia after laparoscopic treatment of hydatid liver cyst: medical and legal concerns of a rare complication. Forensic Sci Int. 2012;219(1–3):
16. Kuzmanovska B, Kartalov A, Kuzmanovski I, et al. Hypernatremia-induced neurologic complications after hepatic hydatid cyst surgery: pretreat to prevent. Med Arch. 2019;73(5):356–8.
17. Akhan O, Salik AE, Ciftci T, Akinci D, Islim F, Akpinar B. Comparison of long-term results of percutaneous treatment techniques for hepatic cystic Echinococcosis Types 2 and 3b. AJR Am J Roentgenol. 2017;208:878–84.
18. Men S, Yücesoy C, Edgiüer TR, Hekimoglu B. Percutaneous treatment of giant abdominal hydatid cysts: long-term results. Surg Endosc. 2006;20:1600–6.
19. Piens MA, Persat F, May F, Mojon M. Praziquantel in human hydatidosis. Evaluation by preoperative treatment; article in French. Bull Soc Pathol Exot Filiaries. 1989;82:503–12.
20. Homeida M, Leaby W, Copeland S, Ali MMM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol. 1994;88:551–9.
21. Cobo F, Yarnoz C, Sesma B, et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus. Trop Med Int Health. 1998;3:462–6.
22. Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop. 2009;111:95–101.
23. Lissandrin R, Tamarozzi F, Mariconti M, Manciulli T, Brunetti E, Vola A. Watch and wait approach for inactive Echinococcal cyst of the liver: an update. Am J Trop Med Hyg. 2018;99:375–9.
24. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. 2012;6:e1475.
25. Torgerson PR. Mathematical models for the control of cystic echinococcosis. Parasitol Int. 2006;55(Suppl):S253–8.
26. Schurer JM, Rafferty E, Farag M, Zeng W, Jenkins EJ. Echinococcosis: an economic evaluation of a veterinary public health intervention in Rural Canada. PLoS Negl Trop Dis. 2015;9:e0003883.
27. Richter J, Esmann L, Lindner AK, et al. Cystic echinococcosis in unaccompanied minor refugees from Afghanistan and the Middle East to Germany, July 2016 through June 2017. Eur J Epidemiol. 2019;34:611–2.
28. Narra R, Maestri M, Budke CM, et al. Costs associated with surgically treated cases of abdominal cystic Echinococcosis: a single center’s experience from 2008 to 2014, Pavia. Italy Am J Trop Med Hyg. 2016;95:405–9.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.